Amylyx Pharmaceuticals, Inc. AMLX Restricted cash equivalents included in Other long-term assets

Restricted cash equivalents included in Other long-term assets at other companies

Slide Insurance Holdings, Inc. Common StockSLDE

$482.05M—

Dyne Therapeutics, Inc.DYN

$15.59M+703%

Liberty Broadband CorporationLBRDK

$46M+142%

Peabody EnergyBTU

$844.1M+4.2%

BlackBerryBB

$14.2M-13.9%

Agilon HealthAGL

$71.58M+4,156%

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s restricted cash equivalents included in other long-term assets?

Amylyx Pharmaceuticals, Inc. (AMLX) reported restricted cash equivalents included in other long-term assets of $986K in Q1 2026.

How has Amylyx Pharmaceuticals, Inc.'s restricted cash equivalents included in other long-term assets changed year-over-year?

Amylyx Pharmaceuticals, Inc.'s restricted cash equivalents included in other long-term assets decreased by 32.0% year-over-year, from $1.45M to $986K.

What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s restricted cash equivalents included in other long-term assets?

Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s restricted cash equivalents included in other long-term assets has grown at a 51.1% compound annual growth rate (CAGR), from $189K to $985K.

What does restricted cash equivalents included in other long-term assets mean?

This represents cash and cash equivalents that are legally restricted from withdrawal or usage for general corporate purposes for a period exceeding one year. These funds are typically held as collateral for long-term lease agreements, debt covenants, or other contractual obligations. Monitoring this balance provides insight into the company's liquidity constraints and the portion of capital tied up in non-operating activities.